Logo Image
Publication|Videos|July 31, 2023

Deep Dive into the Use of Real-World Registry Data as External Control Arms

Author(s)CorEvitas

While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.

Watch this video and learn more:

  • Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
  • The purpose of a control population in traditional randomized controlled clinical trials.
  • How hybrid control arms can improve the strength of control groups.
  • How prospective registries serve as real-world control populations.
  • How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more